Data highlights preclinical efficacy and safety of GNX1021, a novel glycan-targeting ADC, in gastric cancer models NEW TAIPEI CITY, Taiwan, March 27, 2025 /PRNewswire/ -- GlycoNex, Inc. (4168, hereinafter referred to as GNX), a clinical stage biotechnology company focused on the...
Hence then, the article about glyconex to present preclinical data on gnx1021 at aacr 2025 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( GlycoNex to Present Preclinical Data on GNX1021 at AACR 2025 )
Also on site :
- In 1957, Ford launched the Edsel after spending $250 million developing it; two years later Ford discontinued it, having lost $350 million
- In 1948, William Rosenberg used $1,500 in war bonds and a $1,000 loan to open his first coffee shop; Dunkin’ Donuts later sold for $11.3 billion to Inspire Brand
- In 1889, Emile Zatarain began selling root beer from a New Orleans grocery; his family’s spice company sold to McCormick for $180 million in 2003